John Sang Lee - Feb 24, 2022 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc (PHASQ)

Role
Chief Medical Officer
Signature
/s/ John P. Sharp, Attorney-in-fact
Stock symbol
PHASQ
Transactions as of
Feb 24, 2022
Transactions value $
$0
Form type
4
Date filed
2/28/2022, 06:23 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHASQ Restricted Stock Unit Award $0 +24.8K $0.00 24.8K Feb 24, 2022 Common Stock 24.8K Direct F1, F2
transaction PHASQ Employee Stock Option (right to buy) Award $0 +116K $0.00 116K Feb 24, 2022 Common Stock 116K $1.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit is the economic equivalent of one share of PhaseBio Pharmaceuticals, Inc. common stock and is converted into common stock upon vesting subject to the reporting person's continued service through each such date.
F2 These Restricted Stock Units vest in equal one-third amounts on April 1, 2023, 2024, and 2025.
F3 The shares subject to the option shall vest in equal monthly installments over 48 months from February 24, 2022, subject to the reporting person's continued service through each such date.